Literature DB >> 15388584

Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis.

Roshini S Abraham1, Karla V Ballman, Angela Dispenzieri, Diane E Grill, Michelle K Manske, Tammy L Price-Troska, Natalia Gonzalez Paz, Morie A Gertz, Rafael Fonseca.   

Abstract

Immunoglobulin light chain amyloidosis (AL) is characterized by a clonal expansion of plasma cells within the bone marrow. Gene expression analysis was used to identify a unique molecular profile for AL using enriched plasma cells (CD138+) from the bone marrow of 24 patients with AL and 28 patients with multiple myeloma (MM) and 6 healthy controls. Class prediction analysis (PAM) revealed a subset of 12 genes, which included TNFRSF7 (CD27), SDF-1, and PSMA2, that distinguished between these 2 groups with an estimated and observed accuracy of classification of 92%. This model was validated with an independent dataset of 11 patients with AL and 12 patients with MM with 87% accuracy. Differential expression for the most discriminant genes in the 12-gene subset was validated using quantitative real-time polymerase chain reaction and protein expression analysis, which upheld the observations from the micro-array expression data. Functional analyses using a novel network mapping software revealed a number of potentially significant pathways that were dysregulated in patients with AL, with those regulating proliferation, apoptosis, cell signaling, chemotaxis, and migration being substantially represented. This study provides new insight into the molecular profile of clonal plasma cells and its functional relevance in the pathogenesis of light chain amyloidosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15388584     DOI: 10.1182/blood-2004-04-1424

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Clinical implication of centrosome amplification in plasma cell neoplasm.

Authors:  Wee J Chng; Greg J Ahmann; Kim Henderson; Rafael Santana-Davila; Philip R Greipp; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Shaji Kumar; S Vincent Rajkumar; John A Lust; Robert A Kyle; Steven R Zeldenrust; Suzanne R Hayman; Rafael Fonseca
Journal:  Blood       Date:  2005-12-22       Impact factor: 22.113

2.  Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis.

Authors:  Yujia Wang; Lushuang Xu; Yang Liu; Yuzhe Hu; Qiang Shi; Lixue Jin; Lijun Yang; Pingzhang Wang; Kunshan Zhang; Xiaojun Huang; Qing Ge; Jin Lu
Journal:  Int J Hematol       Date:  2020-10-10       Impact factor: 2.490

3.  Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma.

Authors:  Wee J Chng; Roelandt F Schop; Tammy Price-Troska; Irene Ghobrial; Neil Kay; Diane F Jelinek; Morie A Gertz; Angela Dispenzieri; Martha Lacy; Robert A Kyle; Philip R Greipp; Renee C Tschumper; Rafael Fonseca; Peter Leif Bergsagel
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

4.  Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category.

Authors:  E Muchtar; A Dispenzieri; S K Kumar; R P Ketterling; D Dingli; M Q Lacy; F K Buadi; S R Hayman; P Kapoor; N Leung; R Chakraborty; W Gonsalves; R Warsame; T V Kourelis; S Russell; J A Lust; Y Lin; R S Go; S Zeldenrust; R A Kyle; S V Rajkumar; M A Gertz
Journal:  Leukemia       Date:  2016-12-01       Impact factor: 11.528

5.  Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.

Authors:  Alan H Bryce; Rhett P Ketterling; Morie A Gertz; Martha Lacy; Ryan A Knudson; Steven Zeldenrust; Shaji Kumar; Suzanne Hayman; Francis Buadi; Robert A Kyle; Philip R Greipp; John A Lust; Stephen Russell; S Vincent Rajkumar; Rafael Fonseca; Angela Dispenzieri
Journal:  Haematologica       Date:  2009-02-11       Impact factor: 9.941

6.  Cooperation of DLC1 and CDK6 affects breast cancer clinical outcome.

Authors:  Xiaofeng Dai; Lu Li; Xiuxia Liu; Weiguo Hu; Yankun Yang; Zhonghu Bai
Journal:  G3 (Bethesda)       Date:  2014-11-24       Impact factor: 3.154

Review 7.  AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies: JACC: CardioOncology State-of-the-Art Review.

Authors:  Giada Bianchi; Yifei Zhang; Raymond L Comenzo
Journal:  JACC CardioOncol       Date:  2021-10-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.